PureTech Health PLC
NASDAQ:PRTC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
17.08
32.98
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PRTC stock under the Base Case scenario is 9.3658 USD. Compared to the current market price of 19.3615 USD, PureTech Health PLC is Overvalued by 52%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
PureTech Health PLC
Run backtest to discover the historical profit from buying and selling PRTC based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
PureTech Health PLC
Balance Sheet Decomposition
PureTech Health PLC
Current Assets | 508.8m |
Cash & Short-Term Investments | 502.1m |
Receivables | 2.1m |
Other Current Assets | 4.7m |
Non-Current Assets | 71.1m |
Long-Term Investments | 29m |
PP&E | 17.3m |
Intangibles | 906k |
Other Non-Current Assets | 23.9m |
Current Liabilities | 138.3m |
Accounts Payable | 8.1m |
Accrued Liabilities | 23.3m |
Other Current Liabilities | 106.9m |
Non-Current Liabilities | 125.8m |
Long-Term Debt | 16.4m |
Other Non-Current Liabilities | 109.3m |
Earnings Waterfall
PureTech Health PLC
Revenue
|
468k
USD
|
Operating Expenses
|
-136.9m
USD
|
Operating Income
|
-136.4m
USD
|
Other Expenses
|
54m
USD
|
Net Income
|
-82.5m
USD
|
Free Cash Flow Analysis
PureTech Health PLC
USD | |
Free Cash Flow | USD |
PRTC Profitability Score
Profitability Due Diligence
PureTech Health PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
Score
PureTech Health PLC's profitability score is 17/100. The higher the profitability score, the more profitable the company is.
PRTC Solvency Score
Solvency Due Diligence
PureTech Health PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
PureTech Health PLC's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRTC Price Targets Summary
PureTech Health PLC
According to Wall Street analysts, the average 1-year price target for PRTC is 66.6278 USD with a low forecast of 50.5396 USD and a high forecast of 88.6099 USD.
Shareholder Yield
Current shareholder yield for PRTC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
PRTC Price
PureTech Health PLC
Average Annual Return | -0.51% |
Standard Deviation of Annual Returns | 42.22% |
Max Drawdown | -73% |
Market Capitalization | 463.4m USD |
Shares Outstanding | 23 931 900 |
Percentage of Shares Shorted | 0.05% |
Profile
Country
Industry
Market Cap
Dividend Yield
Description
PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The company is headquartered in Boston, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2015-06-19. The firm is engaged in discovering, developing and commercializing medicines for diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm's wholly owned pipeline consists of six therapeutic candidates including LYT-100 (deupirfenidone), LYT-200, LYT-210, LYT-300 (oral allopregnanolone), LYT-500, and LYT-503/IMB-150. Its segments include Internal, Controlled Founded Entity, Non-Controlled Founded Entities, and Parent Company and Other. Its Internal segment is advancing wholly owned programs designed to harness immunological, fibrotic and lymphatic system mechanisms. These classes of immunomodulatory drugs are designed to treat serious diseases, including lung dysfunction, immuno-oncology, lymphatic, neurological and neuropsychological disorders.
Contact
IPO
Employees
Officers
The intrinsic value of one PRTC stock under the Base Case scenario is 9.3658 USD.
Compared to the current market price of 19.3615 USD, PureTech Health PLC is Overvalued by 52%.